eMedicine Specialties > Psychiatry > Adult

Borderline Personality Disorder

Roy H Lubit, MD, PhD, Assistant Clinical Professor, Mount Sinai School of Medicine; Clinical Faculty, Department of Child Psychiatry, New York University School of Medicine; Private Practice
Elizabeth A Finley-Belgrad, MD, Clinical Assistant Professor, Department of Psychiatry, Northeastern Ohio Universities College of Medicine

Updated: Apr 1, 2008

Introduction

Background

Personality traits are enduring patterns of perceiving, relating to, and thinking about the environment and oneself. They are exhibited in a wide range of important social and personal contexts. When these traits are significantly maladaptive and cause serious functional impairment or subjective distress, they constitute a personality disorder. The manifestations of personality disorders are often recognized by adolescence and continue throughout most of adult life.

Personality disorders are not formally diagnosed in patients younger than 18 years because of the ongoing developmental changes. However, if the disturbance is pervasive and if the criteria are fully and persistently met and are not limited to a developmental stage, diagnosing borderline personality disorder (BPD) in children and adolescents is appropriate.

BPD has historically been considered to be on the border between psychosis and neurosis. It is characterized by marked instability in functioning, affect, mood, interpersonal relationships, and, at times, reality testing. In 1942, Deutsch described a group of patients who lacked a consistent sense of identity and source of inner direction.¹ She created the term "as-if personalities" because the patients completely identified with those upon whom they were dependent. In 1975, Kernberg conceptualized BPD to describe a group of patients with particular primitive defense mechanisms and pathologic internalized object relations (eg, splitting, projective identification).²

Borderline pathology in children refers to a syndrome characterized by a combination of externalizing symptoms (disruptive behavioral problems), internalizing symptoms (mood and anxiety symptoms), and cognitive symptoms. Follow-up studies of these children show that they have a tendency to develop a wide range of personality disorders, not specifically BPD. Further research in this area is imperative, not only to elucidate etiology, but also to allow for the earliest possible intervention.

Pathophysiology

Some studies have suggested that patients with BPD might have increased rates of soft neurologic signs,³ as well as learning disorders, attention deficit hyperactivity disorder, and abnormal EEG findings.⁴ Reports also indicate that adults with BPD have increased impulsivity, cognitive inflexibility, and poor self-monitoring and perseveration, which may be indicators of frontal lobe dysfunction.

As with most psychiatric disorders, the etiology of BPD is likely to include several factors, including an organic predisposition as well as psychosocial and environmental factors.

Some researchers postulate the presence of an underlying affective instability to which the individual responds with maladaptive behaviors.

Frequency

United States

To the authors' knowledge, no definitive prevalence studies have been performed; however, BPD is reported to be present in 1-2% of the general population. In a study performed by Clarkin et al in 1983, approximately 11% of psychiatric outpatients and 19% of inpatients met the criteria for BPD.⁵

Mortality/Morbidity

• Premature death among patients with BPD may be due to the increased risk of suicide in this population. Approximately 70-75% of patients with BPD have a history of at least one deliberate act of self-harm. According to Linehan et al, the mean estimated rate of completed suicides 9%.^6,7
• BPD is associated with significant morbidity due to common comorbid conditions, including dysthymia, major depression, psychoactive substance abuse, and psychotic disorders. In a 1999 study of 409 patients, Zimmerman and Mattia demonstrated that patients with BPD were twice as likely to receive a diagnosis of 3 or more current axis-I disorders and that they were nearly 4 times as likely to have a diagnosis of 4 or more axis-I disorders than those without BPD.⁸ These included mood disorders, anxiety, substance abuse, eating disorders, and somatoform disorders.
• Morbidity in this population includes failure in social relationships, developmental delay, and occupational impairment. Health care costs in patients with borderline pathology are enormous, and treatment dropout rates are extraordinarily high.

Race

No evidence suggests a relationship between race and the diagnosis of BPD or borderline disorders of childhood.

Sex

Virtually every study of BPD has revealed that the diagnosis is more common in females than in males; the female-to-male ratios are as high as 4:1.

Age

Symptoms of BPD are usually present by late adolescence, but the diagnosis has been made in children. The initial diagnosis of this disorder is rarely made in patients older than 40 years.

Clinical

History

• In contrast to adult cases of borderline personality disorder (BPD), BPD in childhood has not been consistently and clearly categorized.
  • In the 1940s and 1950s, several researchers categorized this disorder in children in the realm of childhood psychoses or schizophrenia.^9,10 Clinical observations included fluctuations in ego states, primitive regressions, disturbed interpersonal relationships, and severe anxiety.
  • Anna Freud described children with deep levels of regression, massive developmental arrests, withdrawal of libido from the object world and displacement onto the body or self, an inability to receive comfort from others, and numerous specific ego deficits.¹¹
• In 1982, Pine developed a working nosology of borderline syndromes in children.¹² These clinical subgroupings remain highly relevant, although the Diagnostic and Statistical Manual, 4th Edition, (DSM-IV) nomenclature was not modified to establish the diagnosis in patients younger than 18 years.¹³
  • Patients may have failures in developmental lines associated with major ego functions or central aspects of object relationships.
  • Patients may have an inability to adequately soothe themselves, with demonstrations of overemotionality and maladaptive attempts at self-soothing.
  • Patients may have an unstable sense of self that manifests as maladaptive attempts to fulfill their needs by means of suicide threats, self-harm, and angry behavior.
• BPD is considered to have a condition on the border between psychosis and neurosis.
  • The disorder is characterized by marked instability in functioning, affect, mood, interpersonal relationships, and, at times, reality testing.
  • Patients with BPD may manifest overwhelming anger when in a state of crisis.
  • Psychotic symptoms, when present, are short lived, circumscribed, or accompanied by good reality testing.
  • Individuals with personality disorders are frequently dissatisfied with their marked and sustained impairment in social, occupational, or academic functioning.

Physical

• No consistent physical findings are specific to BPD or borderline pathology in children.
• The diagnosis is based on clinical observations of behaviors and patient-reported symptoms.

Causes

• Most theories about the cause or pathogenesis of BPD include the notion of a biologic predisposition¹⁴ along with psychological and environmental factors.
• Several researchers have proposed the existence of a constitutional incapacity to tolerate stress.
• Kernberg has hypothesized that patients with borderline pathology have a constitutional inability to regulate their affect, which predisposes them to psychic disorganization or deterioration under early adverse environmental conditions.²
• Persons with BPD are at higher risk for axis-I syndromes, including depression, panic disorder, and agoraphobia. Studies commonly reveal that patients with BPD are anxious, dependent, and acutely sensitive to rejection and loss; these observations suggest that the condition might be specifically related to attachment bond regulation.
  • Mahler hypothesized that infants at risk are subjected to unpredictable and prolonged separation from their maternal figure during the separation-individuation process of development that occurs around age 18-36 months.⁹ The unavailability of the maternal figure might make the child forever vulnerable to disorganization brought on by separation experiences.
  • Kernberg suggested that patients with BPD internalize early pathologic object relations.² The use of primitive defense mechanisms (which individuals without BPD outgrow during normal development) maintains these early pathologic object relations. Kernberg hypothesized that, in the early stages of development, the infant experiences the maternal figure in 2 contradictory ways: The first is the good mother, who provides for, loves, and remains close. The second is the hateful, depriving mother, who unpredictably punishes and abandons the child. The result is intense anxiety, which leads to the borderline defense of splitting.
  • Several researchers have proposed a hypothesis for borderline personality by using a family systems perspective.¹⁵ In this view, the significant etiologic variables stem from the concepts of faulty family boundaries, the unpredictable proximity among family members, and the lack of an appropriate hierarchical structure.
• Although the borderline condition in childhood is not necessarily a precursor to BPD in adulthood, evidence suggests that both have strikingly similar risk factors, which might indicate a common etiology. These factors include family environments characterized by trauma, neglect, and/or separation; exposure to sexual and physical abuse; and serious parental psychopathology, such as substance abuse and antisocial personality disorder.
• The pathogenesis of borderline personality is complex and probably multifactorial, as in the theory of Linehan et al, which states that borderline pathology results from the interaction of a biologic emotional vulnerability and a pervasively invalidating environment.^6,7 More research involving developmental psychopathology, neurobiology, and family systems theory is necessary to explain how, when, and in what combination these various factors might pathologically affect development.

Differential Diagnoses

Attention Deficit Hyperactivity Disorder
Child Abuse & Neglect: Dissociative Identity Disorder
Child Abuse & Neglect: Posttraumatic Stress Disorder
Mood Disorder: Bipolar Disorder
Posttraumatic Stress Disorder in Children

Other Problems to Be Considered

Numerous studies show that as many as one half of all patients with borderline personality disorder (BPD) may also meet the criteria for histrionic, antisocial, or schizotypal personality disorders. Chronic feelings of emptiness, impulsivity, self-mutilation, short-lived psychotic episodes, and manipulative suicide attempts help to discriminate BPD from other personality disorders. The Gunderson Diagnostic Interview for Borderlines¹⁶ and the Perry Borderline Personality Disorder Scale can be helpful structured tools in the diagnosis of BPD.

Andrulonis evaluated a population of 45 children (aged 5-12 y) who met the Diagnostic and Statistical Manuel, 3rd Edition, (DSM-III) and Gunderson criteria for BPD.¹⁷ The primary behaviors that differentiated these children from the control group were aggression and rage, attention deficit hyperactivity disorder, excessive use of fantasy, impulsivity, and poor relationships.

Workup

Laboratory Studies

• No laboratory tests are useful in identifying this disorder.
• Some patients with borderline personality disorder (BPD) have abnormal results with dexamethasone suppression testing and with abnormal thyrotropin-releasing hormone testing; however, these findings are also present in many patients with depression.
• As with any thorough workup of a patient with a mood disorder, fasting glucose and thyroid function studies are usually indicated.
• Other laboratory tests are indicated depending on the clinical presentation.

Imaging Studies

• No diagnostic imaging studies are specific for borderline disorders in adults or children.

Other Tests

• In one small study of 20 patients with BPD, 40% of patients had abnormal, diffuse, slow activity on EEG findings.⁴
• Some patients with BPD have shortened rapid eye movement (REM) latency and sleep-continuity disturbances, but these findings are also found in a fair number of patients with depression.
• Although psychological testing reveals and highlights the clinical features, it does not increase diagnostic specificity.
  • Most authors agree that patients with BPD demonstrate ordinary reasoning abilities on structured tests with tools such as the Wechsler Adult Intelligence Scale (WAIS).
  • Abnormal processes are noted only on unstructured projective tests, such as the Rorschach test.
  • Projective testing highlights circumstantial reasoning and illogical and unrelated connections. In addition, responses of patients with BPD are often overwhelmingly negative.
• In 1999, Blais et al evaluated the DSM-IV criteria for BPD and indicated that the combination of the following criteria provides the best prediction of inclusion in the borderline or nonborderline group:¹⁸
  • Criterion 1 - Abandonment
  • Criterion 2 - Unstable relationships
  • Criterion 3 - Identity
  • Criterion 6 - Unstable affect

Treatment

Medical Care

• Psychotherapeutic treatment of patients with borderline personality disorder (BPD) is often difficult because of regression, overwhelming affect, and impulsive behavior.
  • Kernberg suggests that a modified psychoanalytic approach is most useful.² The goal of this type of therapy is the resolution of pathologic internalized representations of interpersonal relationships. The therapist requires adequate support systems, including access to prolonged hospitalization, which might be necessary.
  • Another view in the psychotherapeutic treatment of patients with BPD maintains that the regressive transference resulting from analytically oriented treatment is often detrimental to the patient. A supportive, reality-oriented approach in which the goal of therapy is a gradual social adjustment in the framework of a realistic therapeutic relationship is more beneficial.
  • A third viewpoint is that experience rather than explanations benefit the patient. In this approach, the therapist remains calm, without anxiety or anger, while remaining emotionally available. In this setting, the patient learns to tolerate the hateful and destructive feelings that arise because of transference and to eventually replace them with more constructive and positive reactions. The patient also internalizes a calm, soothing supportive object.
• Dialectic behavior therapy (DBT) is a modification of standard cognitive-behavioral techniques designed specifically for the treatment of BPD.¹⁹ Currently, DBT is the only data-supported treatment for BPD. Although DBT was developed as an outpatient program, it has been modified for use in hospital settings and among more diverse populations.
  • The focus of DBT is teaching patients 4 skills: mindfulness (attention to one's experience), interpersonal effectiveness (predominantly assertiveness), emotional regulation, and distress tolerance without impulsivity.
  • In randomized clinical trials, DBT was more effective than usual treatment in reducing suicidal and self-injurious behaviors, treatment dropout, hospitalizations, and self-reports of anger and anxious ruminations.^6,7 Increased rates of global adjustment were observed after one year of treatment, and these gains were maintained over the subsequent year.
• For the treatment of children with BPD traits, family-oriented interventions appear to be superior in benefiting the patient and in diminishing the risk of further undermining parental self-esteem. Many studies of these children highlight the importance of early acquisition of self-control for predicting a good developmental outcome. In 1982, Hanson et al demonstrated that most children and adolescents with traits of BPD appear to benefit from structured day programs with strong behavioral management components.²⁰
• Historically, the treatment of patients with BPD has been difficult. In any treatment approach, the therapist must combine elements of conflict resolution and social learning to minimize and limit aggression and impulsivity. Consultants must be readily available, and the therapist must have access to appropriate hospitalization for periods of severe regression and heightened suicidal risk. However, the therapist must also limit inpatient treatment whenever possible because of the costs and because of the inherent difficulties with inpatient treatment of this population. These difficulties include possible severe regression after admission and destructive countertransference enactments when staff training or supervision is less than ideal. Several authors report that offering a truly appropriate and adequate course of treatment is significantly less costly than the use of crisis interventions when required.

Consultations

• If BPD or borderline disorder of childhood is suspected, consult a child psychiatrist or other appropriately trained mental health professional.

Medication

Patients with borderline personality disorder (BPD) tend to have strong placebo responses to medication; thus, impressive short-term improvement might occur and unexpectedly fade. Impulsivity, affective instability, and psychosis are the significant manifestations of borderline pathology that might require pharmacologic treatment.

Benzodiazepines are contraindicated in this population because they reduce inhibitions and are therefore likely to increase impulsivity. Furthermore, patients with BPD are prone to sedative addiction.

Selective serotonin reuptake inhibitors (SSRIs)

These antidepressant agents are chemically unrelated to the tricyclic, tetracyclic, and other available antidepressants. SSRIs inhibit CNS neuronal reuptake of serotonin (5HT). They may also have a weak effect on norepinephrine and dopamine neuronal reuptake. SSRIs are also used to treat anxiety, phobias, and obsessive-compulsive disorders (OCDs).

When used at high doses, SSRIs appear to reduce impulsivity and aggression; however, the antidepressant effects are less impressive than those of other drugs. One important advantage of SSRIs is their relative safety because patients with BPD commonly take overdoses of their prescribed medication. Therefore, the use of tricyclic antidepressants, lithium, and other mood stabilizers is usually not indicated without specific relevant symptoms and a strong, ongoing therapeutic relationship.

SSRIs are greatly preferred over the other classes of antidepressants. Because the adverse effect profile of SSRIs is less prominent, improved compliance is promoted. SSRIs do not have the cardiac arrhythmia risk associated with tricyclic antidepressants. Arrhythmia risk is especially pertinent in overdose, and suicide risk must always be considered when treating a child or adolescent with mood disorder.

Physicians are advised to be aware of the following information and use appropriate caution when considering treatment with SSRIs in the pediatric population.

In December 2003, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) issued an advisory that most SSRIs are not suitable for use by persons younger than 18 years for treatment of "depressive illness." After review, this agency decided that the risks to pediatric patients outweigh the benefits of treatment with SSRIs, except fluoxetine (Prozac), which appears to have a positive risk-benefit ratio in the treatment of depressive illness in patients younger than 18 years.

In October 2003, the US Food and Drug Administration (FDA) issued a public health advisory regarding reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder. This advisory reported suicidality (both ideation and attempts) in clinical trials of various antidepressant drugs in pediatric patients. The FDA has asked that additional studies be performed because suicidality occurred in both treated and untreated patients with major depression and thus could not be definitively linked to drug treatment.

However, a recent study of more than 65,000 children and adults treated for depression between 1992 and 2002 by the Group Health Cooperative in Seattle found that suicide risk declines, not rises, with the use of antidepressants. This is the largest study to date to address this issue.²¹

Currently, evidence does associate OCD and other anxiety disorders treated with SSRIs with an increased risk of suicide.

Fluoxetine (Prozac)

Selectively inhibits presynaptic serotonin reuptake with minimal or no effect on norepinephrine or dopamine uptake. Was the first available SSRI and remains the prototype. Has longest half-life (72 h). Commonly reported adverse effects (eg, general insomnia, agitation, GI disturbance) generally well tolerated, and discontinuation by the patient is rare.
Increase dose only if improvement not evident. Trial of 6-8 wk may be required before resistance inferred. Higher doses generally more effective in BPD. FDA approved for depression and OCD in children and adolescents.

Dosing

Adult

20-80 mg/d PO

Pediatric

<7 years: Not established
>7 years: 5-10 mg/d PO

Interactions

Potent inhibitor of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 isoenzymes; increases toxicity of diazepam and trazodone by decreasing clearance; increases toxicity of MAOIs and highly protein bound drugs; serotonin syndrome (ie, myoclonus, rigidity, confusion, nausea, hyperthermia, autonomic instability, coma, eventual death) occurs with simultaneous use of other serotonergic agents (eg, anorectic agents, tramadol, buspirone, trazodone, clomipramine, nefazodone, tryptophan), discontinue other serotonergic agents at least 2 wk before SSRI use

Contraindications

Documented hypersensitivity; MAOI use within last 2 wk

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Known or suspected history of mania or hypomania; caution in hepatic impairment and history of seizures; discontinue MAOIs at least 2 wk before therapy; GI disturbance, decreased appetite, weight loss, agitation, insomnia, dream intensification, and male sexual dysfunction possible
Newborn infants exposed to SSRIs during the third trimester of pregnancy have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding

Sertraline (Zoloft)

Shorter half-life (25 h) than that of fluoxetine and has fewer reported adverse effects. Does not increase plasma levels of other psychotropic medications to same extent as fluoxetine. Most commonly reported adverse effects generally well tolerated; discontinuation by the patient is rare. FDA approved for OCD in children >6 y. FDA approved for PTSD in adults. PO liquid concentrate available.

Dosing

Adult

50-200 mg PO qd

Pediatric

<6 years: Not established
6-12 years: 25 mg/d PO initially
>12 years: 50 mg/d PO; may gradually titrate upward; not to exceed 200 mg/d

Interactions

Inhibits CYP2C9, CYP2C19, and CYP3A4 isoenzymes; increases toxicity of MAOIs, diazepam, tolbutamide, and warfarin; serotonin syndrome (ie, myoclonus, rigidity, confusion, nausea, hyperthermia, autonomic instability, coma, eventual death) occurs with simultaneous use of other serotonergic agents (eg, anorectic agents, tramadol, buspirone, trazodone, clomipramine, nefazodone, tryptophan), discontinue other serotonergic agents at least 2 wk before SSRI use

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in preexisting seizure disorders, recent myocardial infarction, unstable heart disease, and hepatic or renal impairment; adverse affects include GI disturbance, slightly decreased appetite, agitation, transient insomnia, decreased libido, and sexual dysfunction
Newborn infants exposed to SSRIs during the third trimester of pregnancy have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding

Antipsychotics

Low-dose neuroleptics are effective in the short term for control of transient psychotic symptoms. Antipsychotics have long been used to control impulsivity and aggression in patients with BPD, although SSRIs are preferred because of their more benign adverse effect profile. If an antipsychotic agent is necessary, avoid butyrophenones in favor of atypical agents such as risperidone.^22,23,24

Risperidone (Risperdal)

Binds to dopamine D2-receptor with an affinity 20 times lower than its affinity for the 5-HT2-receptor. Improves negative symptoms of psychoses and reduces incidence of extrapyramidal adverse effects. Approved for several indications in pediatric patients. Indicated for schizophrenia in adolescents (13-17 y), for bipolar mania in children and adolescents (10-17 y), and in children (5-16 y) with irritability associated with autistic disorder. Available as PO sol.

Dosing

Adult

0.5-2 mg PO bid

Pediatric

0.5 mg PO qd; may gradually increase by 0.5-1 mg/d; typically, no additional benefit is seen with doses >3 mg/d (dose range may vary between 1-6 mg/d)
Administer as single daily dose

Interactions

Inhibitors of CYP2D6 (eg, bupropion, cimetidine, fluoxetine) may decrease clearance, increasing serum levels; coadministration with carbamazepine may decrease effects; may inhibit effects of levodopa; clozapine may increase levels

Contraindications

Documented hypersensitivity; acute neuroleptic malignant syndrome; hyperprolactinemia; comatose or obtunded patients; concurrent high-dose CNS depressants; preexisting bone marrow suppression; subcortical temperature dysregulation

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

May cause extrapyramidal symptoms, orthostatic hypotension, dysphagia, anticholinergic symptoms, sedation, fatigue, and social withdrawal; long-term adverse effects include tardive dyskinesia, hyperprolactinemia, and photosensitivity; neuroleptic malignant syndrome and sudden death are idiosyncratic adverse effects

Opiate receptor antagonist

In 1999, Bohus et al reported a significant reduction in the duration and intensity of dissociative symptoms in a small number of patients with BPD during treatment with naltrexone, an opiate receptor antagonist.²⁵  Evidence suggests that alterations of the endogenous opiate systems contribute to dissociative symptoms in patients with BPD. In a case report, naltrexone was reported decrease self-injurious behavior in a 3 year-old boy.²⁶  

Naltrexone (ReVia)

Cyclopropyl derivative of oxymorphone that acts as a competitive antagonist at opioid receptors.

Dosing

Adult

25-100 mg PO qid; initiate at lower dose and gradually titrate upward q3d according to symptoms

Pediatric

Not established; limited data suggest 0.5-2 mg/kg/d PO for self-injurious behavior in MR and PDD; not established for treatment of dissociative symptoms

Interactions

Inhibits effects of opiates

Contraindications

Documented hypersensitivity; acute hepatitis or liver failure

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in hepatic impairment; sleepiness and aggression possible

Follow-up

Further Inpatient Care

• Inpatient care is generally not indicated, unless the goals of treatment are well defined (see Treatment).

Further Outpatient Care

• Patients usually require long-term treatment with an appropriate therapist in individual and/or group psychotherapy.

Deterrence/Prevention

• To the authors' knowledge, no specific information is available.

Complications

• Ongoing and serious psychosocial dysfunction occurs if borderline personality disorder (BPD) is left untreated.

Prognosis

• Short-term follow-up studies uniformly reveal that patients with BPD change little over time.
  • In a 1998 prospective follow-up study, Links et al reported that almost 50% of their former inpatients with BPD continued to meet diagnostic criteria at 7 years.²⁷
  • Furthermore, these patients have significantly more comorbid personality psychopathology; this finding supported the assertion that the level of pathology at the initial assessment primarily predicts the level of borderline psychopathology.
• The long-term outcome is generally unknown.
  • However, the initial diagnosis of BPD is rarely made in patients older than 40 years.
  • This observation might reflect the evolution of BPD into more stable personality disorders, or perhaps patients with BPD stop seeking help as they age.
• Children with borderline pathology tend to develop a wide range of personality disorders, not necessarily BPD. Andrulonis believes that BPD traits in girls are more likely to evolve toward affective disorders, whereas BPD traits in boys evolve toward episodic dyscontrol syndromes and substance abuse.¹⁷

Patient Education

• For excellent patient education resources, visit eMedicine's Mental Health and Behavior Center. Also, see eMedicine's patient education article Schizophrenia.

Miscellaneous

Medicolegal Pitfalls

• Patients with BPD commonly take overdoses of their prescribed medication.
  • Therefore, the use of tricyclic antidepressants, lithium, and other mood stabilizers is usually not indicated without specific relevant symptoms and a strong, ongoing therapeutic relationship. Prescribing medication in the absence of ongoing individual or group psychotherapy is not appropriate.
  • SSRIs should be the first drug of choice for the treatment of most symptoms because of their relative safety.
• Antipsychotic medications might cause serious and permanent adverse effects, such as tardive dyskinesia or neuroleptic malignant syndrome.
  • This possibility is also true of atypical agents, such as risperidone, as well as typical neuroleptics.
  • Antipsychotics should be used (1) only for the treatment of transient psychotic symptoms (sometimes present in patients with BPD), (2) at the lowest doses, and (3) for the shortest duration possible.
• Although patients with BPD often use suicide threats in a manipulative manner, the primary care clinician must never ignore these threats or suicide attempts. In children and adolescents, any suicide attempt should be treated with a thorough psychiatric evaluation and with appropriate inpatient hospitalization to ensure the patient's safety.
• Because of the boundary issues in patients with BPD, primary care clinicians must be extremely careful not to become intimately involved with such patients.
  • No sexual activity between a clinician and a patient is ever appropriate, even if the person is no longer an active patient. The ethical standard for psychiatry is this: Once a patient, always a patient.
  • Furthermore, because of the instability and pervasive anger of many patients with BPD, false accusations might be made; therefore, the clinician might need to take extra care in avoiding even the appearance of impropriety.

References

1. Deutsch H. Some forms of emotional disturbance and their relationship to schizophrenia. 1942. Psychoanal Q. Apr 2007;76(2):325-44; discussion 345-86. [Medline].

2. Kernberg OF. Borderline Conditions and Pathological Narcissism. New York, NY: Aronson; 1975.

3. Marcus J, Ovsiew F, Hans S. Neurological dysfunction in borderline children. In: The Borderline Child. New York, NY: McGraw Hill; 1982:171.

4. De la Fuente JM, Tugendhaft P, Mavroudakis N. Electroencephalographic abnormalities in borderline personality disorder. Psychiatry Res. Feb 9 1998;77(2):131-8. [Medline].

5. Clarkin JF, Widiger TA, Frances A, et al. Prototypic typology and the borderline personality disorder. J Abnorm Psychol. Aug 1983;92(3):263-75. [Medline].

6. Linehan MM, Heard HL, Armstrong HE. Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients [published erratum appears in Arch Gen Psychiatry 1994 May;51(5):422]. Arch Gen Psychiatry. Dec 1993;50(12):971-4. [Medline].

7. Linehan MM, Tutek DA, Heard HL, Armstrong HE. Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. Am J Psychiatry. Dec 1994;151(12):1771-6. [Medline].

8. Zimmerman M, Mattia JI. Axis I diagnostic comorbidity and borderline personality disorder. Compr Psychiatry. Jul-Aug 1999;40(4):245-52. [Medline].

9. Mahler M, Ross J, Defries Z. Clinical studies in benign and malignant cases of childhood psychosis. Am J Orthopsychiatry. 1949;19:295.

10. Weil A. Certain severe disturbances of ego development in children. Psychoanal Study Child. 1953;8:271.

11. Freud A. The assessment of borderline cases. In: The Writings of Anna Freud. Vol 5. New York, NY: International Universities Press; 1969.

12. Pine F. A working nosology of borderline syndromes in children. In: The Borderline Child. New York, NY: McGraw Hill; 1982:83.

13. APA. Diagnostic and Statistical Manual of Mental Disorders. 4^th ed. Washington, DC: American Psychiatric Association; 1994.

14. Baird AA, Veague HB, Rabbitt CE. Developmental precipitants of borderline personality disorder. Dev Psychopathol. Fall 2005;17(4):1031-49. [Medline].

15. Combrinck-Graham L. The borderline syndrome in childhood: a family systems approach. J Psychother Fam. 1989;5:31-34.

16. Block MJ, Westen D, Ludolph P, et al. Distinguishing female borderline adolescents from normal and other disturbed female adolescents. Psychiatry. Feb 1991;54(1):89-103. [Medline].

17. Andrulonis PA. Paper presented at: Annual Meeting of the American Psychiatric Association. Borderline personality subcategories in children. 1990.

18. Blais MA, Hilsenroth MJ, Fowler JC. Diagnostic efficiency and hierarchical functioning of the DSM-IV borderline personality disorder criteria. J Nerv Ment Dis. Mar 1999;187(3):167-73. [Medline].

19. Bernhardt K, Friege L, Gerok-Falke K, Aldenhoff JB. [In-patient treatment concept for acute crises of borderline patients on the basis of dialectical-behavioral therapy]. Psychother Psychosom Med Psychol. Sep 2005;55(9-10):397-404. [Medline].

20. Hanson G, Bemporad JR, Smith HF, Chicchetti D. The day and residential treatment of the borderline child. In: The Borderline Child. New York, NY: McGraw Hill; 1982:235.

21. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. Jan 2006;163(1):41-7. [Medline]. [Full Text].

22. McClellan J, Sikich L, Findling RL, et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry. Aug 2007;46(8):969-78. [Medline].

23. Meighen KG, Hines LA, Lagges AM. Risperidone treatment of preschool children with thermal burns and acute stress disorder. J Child Adolesc Psychopharmacol. Apr 2007;17(2):223-32. [Medline].

24. [Best Evidence] Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. May 2007;46(5):558-65. [Medline].

25. Bohus MJ, Landwehrmeyer GB, Stiglmayr CE, et al. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry. Sep 1999;60(9):598-603. [Medline].

26. White T, Schultz SK. Naltrexone treatment for a 3-year-old boy with self-injurious behavior. Am J Psychiatry. Oct 2000;157(10):1574-82. [Medline].

27. Links PS, Heslegrave R, van Reekum R. Prospective follow-up study of borderline personality disorder: prognosis, prediction of outcome, and Axis II comorbidity. Can J Psychiatry. Apr 1998;43(3):265-70. [Medline].

28. Bemporad JR, Smith HF, Hanson G, Cicchetti D. Borderline syndromes in childhood: criteria for diagnosis. Am J Psychiatry. May 1982;139(5):596-602. [Medline].

29. Classen CC, Pain C, Field NP, Woods P. Posttraumatic personality disorder: a reformulation of complex posttraumatic stress disorder and borderline personality disorder. Psychiatr Clin North Am. Mar 2006;29(1):87-112, viii-ix. [Medline].

30. Crick NR, Murray-Close D, Woods K. Borderline personality features in childhood: a short-term longitudinal study. Dev Psychopathol. Fall 2005;17(4):1051-70. [Medline].

31. Engel M. Psychological testing of borderline children. Arch Gen Psychiatry. 1963;8:426.

32. Faulkner CJ, Grapentine WL, Francis G. A behavioral comparison of female adolescent inpatients with and without borderline personality disorder. Compr Psychiatry. Nov-Dec 1999;40(6):429-33. [Medline].

33. Fuchs T. Fragmented selves: temporality and identity in borderline personality disorder. Psychopathology. 2007;40(6):379-87. [Medline].

34. Goldman SJ, D'Angelo EJ, DeMaso DR. Psychopathology in the families of children and adolescents with borderline personality disorder. Am J Psychiatry. Dec 1993;150(12):1832-5. [Medline].

35. Goldman SJ, D'Angelo EJ, DeMaso DR, Mezzacappa E. Physical and sexual abuse histories among children with borderline personality disorder. Am J Psychiatry. Dec 1992;149(12):1723-6. [Medline].

36. Gollan JK, Lee R, Coccaro EF. Developmental psychopathology and neurobiology of aggression. Dev Psychopathol. Fall 2005;17(4):1151-71. [Medline].

37. Judd P, Rugg R. Neuropsychological dysfunction in borderline personality disorder. J Personal Disord. 1993;7:275-84.

38. Kaplan HI, Sadock BJ. Personality disorders. In: Synopsis of Psychiatry. 5^th ed. Baltimore, Md: Lippincott Williams & Wilkins; 1988:439.

39. Kestenbaum CJ. The borderline child at risk for major psychiatric disorder in adult life. In: The Borderline Child. New York, NY: McGraw Hill; 1982:49-82.

40. Leichtman M, Shapiro S. A clinical approach to the psychological testing of borderline children. In: The Borderline Child. New York, NY: McGraw Hill; 1982:121.

41. Lincoln AJ, Bloom D, Katz M, Boksenbaum N. Neuropsychological and neurophysiological indices of auditory processing impairment in children with multiple complex developmental disorder. J Am Acad Child Adolesc Psychiatry. Jan 1998;37(1):100-12. [Medline].

42. Livesley WJ. Progress in the treatment of borderline personality disorder. Can J Psychiatry. Jul 2005;50(8):433-4. [Medline].

43. Lofgren DP, Bemporad J, King J, et al. A prospective follow-up study of so-called borderline children. Am J Psychiatry. Nov 1991;148(11):1541-7. [Medline].

44. Milman DH. Minimal brain dysfunction in childhood: outcome in late adolescence and early adult years. J Clin Psychiatry. Sep 1979;40(9):371-80. [Medline].

45. Mischel W, Shoda Y, Rodriguez MI. Delay of gratification in children. Science. May 26 1989;244(4907):933-8. [Medline].

46. O'Leary KM, Brouwers P, Gardner DL, Cowdry RW. Neuropsychological testing of patients with borderline personality disorder. Am J Psychiatry. Jan 1991;148(1):106-11. [Medline].

47. O'Leary KM, Cowdry RW. Neuropsychological testing results with patients with borderline personality disorder. In: Silk KR, ed. Biological and Neurobehavioral Studies of Borderline Personality Disorder. Washington, DC: American Psychiatric Press; 1994:127-58.

48. Paris J. Recent advances in the treatment of borderline personality disorder. Can J Psychiatry. Jul 2005;50(8):435-41. [Medline].

49. Paris J, Zelkowitz P, Guzder J, et al. Neuropsychological factors associated with borderline pathology in children. J Am Acad Child Adolesc Psychiatry. Jun 1999;38(6):770-4. [Medline].

50. Petti TA, Vela RM. Borderline disorders of childhood: an overview. J Am Acad Child Adolesc Psychiatry. May 1990;29(3):327-37. [Medline].

51. Robson KS. Borderline disorders. In: Child and Adolescent Psychiatry: A Comprehensive Textbook. 4^th ed. Baltimore, Md: Lippincott Williams & Wilkins; 1985:731.

52. Rutter M. Epidemiological approaches to developmental psychopathology. Arch Gen Psychiatry. May 1988;45(5):486-95. [Medline].

53. Sharp C, Romero C. Borderline personality disorder: a comparison between children and adults. Bull Menninger Clin. Spring 2007;71(2):85-114. [Medline].

54. Simeon D, Nelson D, Elias R, et al. Relationship of personality to dissociation and childhood trauma in borderline personality disorder. CNS Spectr. Oct 2003;8(10):755-62. [Medline].

55. Simpson EB, Pistorello J, Begin A, et al. Use of dialectical behavior therapy in a partial hospital program for women with borderline personality disorder. Psychiatr Serv. May 1998;49(5):669-73. [Medline]. [Full Text].

56. Stevenson J, Meares R. Psychotherapy with borderline patients: II. A preliminary cost benefit study. Aust N Z J Psychiatry. Aug 1999;33(4):473-7; discussion 478-81. [Medline].

57. Towbin KE, Dykens EM, Pearson GS, Cohen DJ. Conceptualizing "borderline syndrome of childhood" and "childhood schizophrenia" as a developmental disorder. J Am Acad Child Adolesc Psychiatry. Jul 1993;32(4):775-82. [Medline].

58. Vaillant GE, Perry JC. Personality disorders. In: Comprehensive Textbook of Psychiatry/IV. Baltimore, Md: Lippincott Williams & Wilkins; 1985:978-81.

59. Widiger TA, Frances AJ. Epidemiology, diagnosis, and comorbidity of borderline personality disorder. In: American Psychiatric Press Review of Psychiatry. Vol 8. Washington, DC: American Psychiatric Press; 1989.

Keywords

BPD, borderline personality, borderline personality disorder, borderline disorder, multiple complex developmental disorder, borderline disorder of childhood, borderline syndrome, schizophrenia, as-if personalities, pseudoneurotic schizophrenia, disorder of character, personality traits, psychiatric disorder, learning disabilities, attention deficit disorder, abnormal electroencephalograms, increased impulsivity

cognitive inflexibility, poor self-monitoring, poor perseveration, frontal lobe dysfunction, neurodevelopmental delays, unusual central nervous system sensitivities, increased risk of suicide, dysthymia, major depression, psychoactive substance abuse, psychotic disorders, mood disorders, anxiety, substance abuse, eating disorders, somatoform disorders, fluctuations in ego states, primitive regressions, disturbed interpersonal relationships, axis-I syndromes, panic disorder, agoraphobia, sexual abuse, physical abuse, parental psychopathology, antisocial personality disorder

Contributor Information and Disclosures

Author

Roy H Lubit, MD, PhD, Assistant Clinical Professor, Mount Sinai School of Medicine; Clinical Faculty, Department of Child Psychiatry, New York University School of Medicine; Private Practice
Disclosure: Nothing to disclose.

Coauthor(s)

Elizabeth A Finley-Belgrad, MD, Clinical Assistant Professor, Department of Psychiatry, Northeastern Ohio Universities College of Medicine
Elizabeth A Finley-Belgrad, MD is a member of the following medical societies: American Academy of Child and Adolescent Psychiatry
Disclosure: Nothing to disclose.

Medical Editor

Carol Diane Berkowitz, MD, Executive Vice Chair, Department of Pediatrics, Professor, Harbor-University of California at Los Angeles Medical Center
Carol Diane Berkowitz, MD is a member of the following medical societies: Alpha Omega Alpha, Ambulatory Pediatric Association, American Academy of Pediatrics, American College of Emergency Physicians, American Medical Association, American Pediatric Society, and North American Society for Pediatric and Adolescent Gynecology
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

CME Editor

Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine
Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine
Disclosure: Baxter Honoraria Consulting

Chief Editor

Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA
Stephen Soreff, MD is a member of the following medical societies: American College of Mental Health Administration and American Psychosomatic Society
Disclosure: Nothing to disclose.

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Joseph A Davies, MD, to the development and writing of this article.

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)